News Related to Severe Asthma

Related coverage linked through entity extraction aliases.

Upstream Bio Reports Positive Phase 2 Data for Verekitug in Nasal Polyps and Severe Asthma

Mar 01, 2026

Upstream Bio presented additional Phase 2 VIBRANT trial data showing verekitug reduced nasal polyp scores and congestion in chronic rhinosinusitis patients, while Phase 2 VALIANT trial results demonstrated significant reductions in asthma exacerbations with multiple dosing regimens.

European Commission Approves Exdensur for Severe Asthma and Chronic Rhinosinusitis

Feb 17, 2026

The European Commission has approved GSK's Exdensur (depemokimab) as the first ultra-long-acting biologic for severe asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps, offering twice-yearly dosing based on positive phase 3 trial results.